Related Experiment Video

Updated: May 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Device-based therapies for resistant hypertension

Rosa Maria Bruno1, Alessia Di Giulio, Giampaolo Bernini

  • 1Department of Internal Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy. rosam.bruno@gmail.com

Current Pharmaceutical Design
|November 24, 2012
PubMed

Insights

Resistant hypertension, a challenging condition, requires new treatments. Device-based therapies targeting the sympathetic nervous system show promise for improving cardiovascular outcomes in these patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Neurology

Background:

  • Hypertension is a leading cardiovascular risk factor, yet control remains suboptimal.
  • Resistant hypertension affects a significant patient group and carries a poor prognosis.
  • Novel therapeutic strategies are needed to reduce cardiovascular risk.

Purpose of the Study:

  • To review clinical aspects of resistant hypertension.
  • To explore the role of autonomic modulation in hypertension treatment.
  • To evaluate device-based therapies for resistant hypertension.

Main Methods:

  • Literature review of clinical studies and physiological mechanisms.
  • Analysis of physiopathological basis of autonomic nervous system in hypertension.
  • Assessment of efficacy and safety data for device-based therapies.

Main Results:

  • Resistant hypertension is prevalent and linked to worse cardiovascular outcomes.
  • The sympathetic nervous system plays a key role in hypertension.
  • Renal denervation and baroceptor-activating therapy are emerging non-pharmacological options.

Conclusions:

  • Device-based therapies targeting the sympathetic nervous system offer new avenues for resistant hypertension.
  • Further research is needed to establish long-term efficacy and safety.
  • Autonomic modulation presents a promising frontier in hypertension management.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...